The Edward Cancer Centers are committed to providing the most up to date cancer treatment options for our patients. One way we do this is by encouraging participation in clinical trials. The Edward Cancer Centers have one of the most active cancer research programs in Dupage County, offering many of the same research trials found at university hospitals.
The research program at Edward Cancer Center has national cancer studies available through their membership in SWOG (Southwest Oncology Group) and The NSABP (National Surgical Adjuvant Breast and Bowel Project). We have access to other cancer research trials through CTSU (Cancer Trials Support Unit). We also work with various pharmaceutical companies that offer cancer clinical trials such as: Bristol Myers Squibb, Sanofi-Aventis, Johnson and Johnson, Glaxo Smith Kline and Roche.
New Edward Cancer Centers Clinical Trials Currently, we are one of only five sites in the United States that have a study open for a rare type of sarcoma, metastatic chondrosarcoma. These patients have essentially few or no options for treatment. This study will be looking at the oral drug, Pazopanib and its effects on patients with chondrosarcoma. The study is sponsored by Glaxo Smith Kline. Dr. Samir Undevia, the principal investigator of this study, is an expert in treating many types of sarcoma, including chondrosarcomas. He is also the Director of the Bone and Soft Tissue Sarcoma Program at the University of Chicago. If you are interested in more information on this trial, please call the Cancer Center Research Office at (630) 646-6075.
Edward Cancer Center is one of only 4 sites in the Chicago Area that will be offering and international breast cancer trial called "The APHINITY Study". This study is sponsored by the pharmaceutical companies F. Hoffmann-La Roche Ltd and Genetech, Inc. This phase III study will be comparing the standard treatment: chemotherapy plus trastuzumab(Herceptin) and placebo with the investigational treatment: chemotherapy plus trastuzuamb and the new agent Pertuzumab in paitents with HER2 positive breast cancer. If you are interested in more information on this trial, please call the Cancer Center Research Office at (630) 646-6075.
We also work in partnership with several national organizations including: